Pateclizumab Biosimilar, Anti-human LT alpha (LT-α) Monoclonal Antibody
The cheapest research grade pateclizumab biosimilar (anti-human lymphotoxin alpha (LT-α) monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by pateclizumab. The research grade pateclizumab biosimilar protein is for research use only.
Synonyms: Lymphotoxin-alpha, LT-α, tumor necrosis factor-beta, TNF-β, TNF beta, LTA, LT, TNFB, TNFSF1, Lymphotoxin alpha, TNLG1E
产品参数
| 货号 | C060P |
|---|---|
| 产品名称 | Pateclizumab Biosimilar, Anti-human LT alpha (LT-α) Monoclonal Antibody |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 同种型 | Human IgG1 kappa. |
| 来源 | The anti-human lymphotoxin alpha (LT-α) monoclonal antibody pateclizumab biosimilar was produced in mammalian cells. |
| 特异性 | The in vivo grade pateclizumab biosimilar specifically binds to the human lymphotoxin alpha (LT-α). |
| 抗体形式 | 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |
| 内毒素 | < 0.1 EU per 1 ug of the protein by the LAL method. |
| 纯度 | >95% by SDS-PAGE under reducing conditions and HPLC. |
| 运输 | The research grade pateclizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| 稳定性与存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
文献
C060P: Pateclizumab Biosimilar (Research Grade), Anti-human Lymphotoxin Alpha (LT-α) Monoclonal Antibody
Recombinant Humanized IgG1 kappa Monoclonal Antibody.
Background
Pateclizumab Biosimilar uses the same protein sequences as the therapeutic antibody pateclizumab.
Pateclizumab is an immunoglobulin G1 kappa (IgG1κ) monoclonal antibody targeting lymphotoxin alpha (LT-α) for the treatment of rheumatoid arthritis. A phase I study has assessed the safety, pharmacokinetics, and biologic activity of pateclizumab, and found that pateclizumab was generally well-tolerated in RA patients. Pateclizumab also has been investigated in clinical trial to study its efficacy and safety in combination with a disease-modifying anti-rheumatic drug (DMARD) compared with adalimumab in combination with a DMARD in patients with active rheumatoid arthritis.
LT-α is a member of tumor necrosis factor superfamily family (TNFSF) and products by predominately by activated cells of the innate and adaptive immune response. Lymphotoxin α formerly named tumor necrosis factor-beta (TNF-β) as it is a homologous protein to TNFα. When LTβ is discovered, TNF-β was renamed LT-α. LT-α plays different roles in immune regulation as its different secreted forms. LTα binds to TNF receptor 1 (TNFR1) and TNFR2 to promote inflammation as a form of soluble homotrimeric molecule (LTα3); whereas cell-bound LTα1β2 (LT-α complex with LTβ as LTα1β2 heterotrimers on the surface of activated B, Th1 and Th17 cells) bind LTβ receptors (LTβR) to mediate signaling pathway.
Rheumatoid arthritis (RA) is an autoimmune disorder associated with progressive joint damage, pain, fatigue, and disability. TNF α is reported to be the main factor promoting the development of RA, so targeting TNFα is regarded as the routine method of RA treatment. However, a large number of RA patients did not respond to TNFα therapy, which prompted us to seek new treatments. In addition to TNFα, other cytokines have also been reported to be involved in the pathogenesis of RA, and LT- α is one of them. It was found that two forms of LTα homotrimer (LTα3 and LTα1β2) increased in synovial fluid of RA patients, while the LTα, LTβ and LTβR transcripts increased in synovium respectively. Study has demonstrated that the depletion of CD4 T helper (Th) subsets Th1 and Th17 (with high levels of surface LTα1β2) by mouse LTα specific monoclonal antibody showed therapeutic efficacy in the preclinical mouse model of RA, which suggests the treatment possibility targeting LTα. Thus, humanized pateclizumab was designed to target LTα, binding to both the soluble LTα3 homotrimeric form and the surface-expressed LTα1β2 heterotrimer, for the treatement of RA. By blocking the binding of LTα3 and LTα1β2 to its cognate receptors LTβR and TNFR, pateclizumab specificly deplete of activated cells and inhibit the immune cell trafficking and/or recruitment to inflammatory sites. Depletion is limited to cells that express LTα1β2 on the surface, which improves the targeting of therapy.